Neurogene (NGNE) Non-Current Debt (2013)
Neurogene posted quarterly Non-Current Debt of $2.0 million for Q4 2013.
Neurogene (NGNE) has 1 years of Non-Current Debt data on file, last reported at $2.0 million in Q4 2013.
- For the quarter ending Q4 2013, Non-Current Debt changed N/A year-over-year to $2.0 million; the trailing twelve-month figure through Dec 2013 stood at $2.0 million (changed N/A YoY), and the FY2013 full-year result was $2.0 million, changed N/A from the prior year.
- Non-Current Debt for Q4 2013 stood at $2.0 million.
- Across five years, Non-Current Debt topped out at $2.0 million in Q4 2013 and bottomed at $2.0 million in Q4 2013.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 319.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 105.94 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 1.99 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Neurogene | 632.14 Mn | 632.14 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2013 | 2.04 Mn |
| Dec 31, 2013 | 2.04 Mn |